A detailed history of Core Alternative Capital transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Core Alternative Capital holds 180 shares of TGTX stock, worth $6,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares
180
Holding current value
$6,004
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 29, 2025

BUY
$21.31 - $35.09 $3,835 - $6,316
180 New
180 $5,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.85B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Core Alternative Capital Portfolio

Follow Core Alternative Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.